Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- The need to characterise SARS-CoV-2-specific T-cells from recovered patients
- Discovery of similar SARS-CoV-2-specific T-cells in healthy volunteers
- Possible reasons for presence of SARS-2-specific T-cells in healthy volunteers
- Differences in actions and behaviours of SARS-2-specific T-cells in patients versus volunteers
- Role of SARS-2-specific T-cells in conferring pre-existing immunity to COVID-19 (i.e. asymptomatic infections)
- Possible implications of the presence of such cells on disease progression
- Implications for vaccine development
Biography
Dr. Nina Le Bert is currently a Senior Research Fellow in the Emerging Infectious Diseases Programme of DUKE-NUS Medical School in Singapore. She earned her Master of Science degree at the Free University of Berlin in Germany, and her PhD from the University College London, UK, in 2011, working in the field of human innate and adaptive immunity. In 2014, she joined Professor Antonio Bertoletti’s lab, where she is investigating virus-specific B and T cell responses during Hepatitis B Virus infection to better understand their role in protection and/or liver pathology. Since the outbreak of the COVID19 pandemic, she is involved in studies of SARS-CoV-2 specific T cells.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Le Bert, N. (2020, September 24). Presence and function of SARS-CoV-2-specific T-cells in recovered patients and healthy volunteers [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 1, 2023, from https://hstalks.com/bs/4416/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Nina Le Bert has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Presence and function of SARS-CoV-2-specific T-cells in recovered patients and healthy volunteers
Published on September 24, 2020
9 min
Other Talks in the Series: Interviews on Covid-19
Transcript
0:00
Interviewer: Dr. Nina Le Bert,
thank you very much for taking the time to do this interview with us today.
To discuss the nature of SARS-CoV-2 specific T-cells in COVID-19 patients,
versus those found in healthy volunteers that have never gotten COVID-19.
Let me jump right in and ask you if you could provide us
with some more background to the research you conducted,
and what specific immunological processes
were you initially trying to investigate in this research?
Dr. Le Bert: In our lab we have always been interested in T-cells.
That's why, in our labs, for many years we have been studying hepatitis B virus specific T-cells.
In antiviral immunity, not only antibodies exist.
T-cells particularly important in viral disease,
because they are recognizing infected cells.
Because the virus is going inside the cell,
and shielding itself from antibody recognition.
And only the T-cells can recognize and then later
lyse cells that have been infected with a virus.
So when the COVID-19 pandemic started and reached here in Singapore,
it was normal for us to start studying SARS-CoV-2 specific T-cells.
Because we know that T-cells are often playing an essential role in viral control.
When we started our work,
we were initially asking to what we think important questions.
Are SARS-CoV-2 specific T-cells induced in COVID-19 recovered patients,
in people who recovered from the disease?
Second question, I think even maybe more important.
Are SARS-CoV-2 specific T-cells persisting for a long time?
The second question isn't trivial because it's a new virus.
Hide